Copy Link Print Information

SKL2001

66 Cited Publications
Revisión del cliente

Based on 66 publication(s) in Google Scholar

SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.66%
  • No. CAS: 909089-13-0
  • Fòrmula: C14H14N4O3
  • Peso molecular:286.29
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • SKL2001 Chemical Structure
    SKL2001 Chemical Structure
  • Experimental Validation Results for SKL2001
  • Experimental Validation Results for SKL2001
  • Experimental Validation Results for SKL2001
  • Experimental Validation Results for SKL2001
  • Experimental Validation Results for SKL2001
  • Experimental Validation Results for SKL2001
No. CAS: 909089-13-0
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of SKL2001:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) SKL2001

More
Customer Validation & Images
WBIn Vivo ImagingHistological Imaging/StainingIn Vivo Efficacy Study
  • WB
  • In Vivo Imaging
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
  • WB
  • WB

Ver todos los productos específicos de isoformas Wnt

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • SKL2001 Chemical Structure
    SKL2001 Chemical Structure
    1/16
  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Apr 19:S2090-1232(25)00273-5. [Abstract]

    Customer Validation
     Wnt/β-catenin activator SKL2001 (40 μM; 3 days) counteracted the promoting effect of AS-II on the Wnt/β-catenin signaling pathway in MO3.13 cells.

  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Aug 13:8:0828. [Abstract]

    Customer Validation
     Schematic of experimental treatment of GL261-luc orthotopic model. Mice (n = 8) were treated with DMSO, ISP-I (50 mg/kg), SKL2001 (10 mg/kg), XAV939 (10 mg/kg), ISP-I (50 mg/kg) + SKL2001 (10 mg/kg), or ISP-I (50 mg/kg) + XAV939 (10 mg/kg) daily via oral gavage for 21 days. Assessment of tumor growth in each group was qualified by bioluminescence imaging.

  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Aug 13:8:0828. [Abstract]

    Customer Validation
     Schematic of experimental treatment of GL261-luc orthotopic model. Mice (n = 8) were treated with DMSO, ISP-I (50 mg/kg), SKL2001 (10 mg/kg), XAV939 (10 mg/kg), ISP-I (50 mg/kg) + SKL2001 (10 mg/kg), or ISP-I (50 mg/kg) + XAV939 (10 mg/kg) daily via oral gavage for 21 days. Representative HE staining images of mouse cerebral tissues from each group, depicting tumor volumes.

  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Aug 13:8:0828. [Abstract]

    Customer Validation
     Schematic of experimental treatment of GL261-luc orthotopic model. Mice (n = 8) were treated with DMSO, ISP-I (50 mg/kg), SKL2001 (10 mg/kg), XAV939 (10 mg/kg), ISP-I (50 mg/kg) + SKL2001 (10 mg/kg), or ISP-I (50 mg/kg) + XAV939 (10 mg/kg) daily via oral gavage for 21 days. The wet weight of collected tumors from each group was measured.

  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2022 Sep:40:197-206. [Abstract]

    Customer Validation
     Western blot and averaged data showing the protein levels of profibrogenic proteins Col1 and α-SMA in TGF-β1-stimulated PAFs with/without FABP5 knockdown treated with/without Wnt/β-catenin pathway agonist SKL2001 (20 μM; 24 h) were presented.

  • 1/16

    SKL2001 purchased from MedChemExpress. Usage Cited in: Mol Ther Nucleic Acids. 2020 Sep 4:21:577-591. [Abstract]

    Customer Validation
     Western blotting confirmed that β-catenin signaling is activated after GC cells are cultured with SKL2001 (40 μM), accompanied by the enhanced expression of the downstream molecules Cyclin D1, c-Myc, and nuclear β-catenin in BGC-823 cells.

  • SKL2001